Simposio internacional: "Translational and reverse-translational research in cancer immunotherapy"

PROGRAMA CIENTÍFICO / SCIENTIFIC PROGRAM

Jueves 29 de septiembre  / 29September (Thursday)

08.30 - 09.00. Inscripciones y recogida de documentación / Registration and documentation collection

09.00 - 09.15 INAUGURACIÓN / OPENING
Raimundo Pérez-Hernández y Torra, Mariano Barbacid e Ignacio Melero

09.15 - 11.30 CONFERENCIAS/ KEYNOTE LECTURES 
Chairs: Estela Paz. Hospital 12 de Octubre and Juan José Lasarte. CIMA

• 09.15 - 09.50 Intravital imaging of immunotherapy. Philippe Bousso. Institut Pasteur. Paris
• 09.50 - 10.00 Q&A
• 10.00 - 10.35 Immunotherapy for ovarian cancer. George Coukos. University of Lausanne
• 10.35 - 10.45 Q&A
• 10.45 - 11.20 HLA Class-I loss and cancer immune escape. FedeThe rico Garrido. University of Granada. Spain
• 11.20 - 11.30 Q&A

11.30 - 12.00 Descanso café / Coffee break

12.00 - 13.45 SESIÓN 1 / SESSION 1
Chair: Miguel Fernández de Sanmamed. CIMA y CUN. Spain

• 12.00 - 12.30 Novel mechanisms of immune escape in HCC. Amaia Lujambio. Icahn School of Medicine at Mount Sinai. NYC
• 12.30 - 13.00 Natural conventional Dendritic cells and their metabolism in cancer immunotherapy. David Sancho. CNIC. Madrid
• 13.00 - 13.30 CD137 (4-1BB)-based immunotherapy: 25th anniversary Ignacio Melero. CIMA y CUN. Spain
• 13.30 - 13.45 Q&A

13.45 - 15.30 COMIDA / LUNCH

15.30 - 17.15 SESIÓN 2 / SESSION 2 
Chair: Sandra Hervás. CIMA

• 15:30 - 16.00 Adoptive T cell therapy in melanoma management. Inge Marie Svane. Center for Cancer Immune Therapy (CCIT). Copenhagen
• 16.00 - 16.30 Innovation in the CAR T cell arena. Sònia Guedan. Hospital Clinic Barcelona. Spain
• 16.30 - 17.00 Adoptive T cell therapy based on neoantigens. Sthephanie Goff. National Cancer Institute. Bethesda, USA
• 17.00 - 17.15 Q&A

17.15 - 17.50 CONFERENCIAS (con patrocinio de Highlight Therapeutics) / KEYNOTE LECTURE (sponsored by Highlight Therapeutics)

Chair: Marisol Quintero. Highlight Therapeutics

• 17.15 - 17.50 Deciphering the mechanisms of cancer immunotherapy. Ira Mellman. Genentech. Los Ángeles, USA.
• 17.50 - 18.00 Q&A

18.00 - 18.35 SESIÓN 3 / SESSION 3
Chair: Antonio González. CUN. Spain

• 18.00 - 18.30 Neoadjuvant approaches in cancer immunotherapy. Christian Blank. Netherlands Cancer Institute. The Netherlands
• 18.30 - 18.35 Q&A

Cena de conferenciantes / Speakers’ dinner

Viernes 30 de septiembre  / 30September (Friday)

9.00 - 10.30 CONFERENCIAS/ KEYNOTE LECTURES
Chair: Pedro Berraondo. CIMA

• 9.00 - 9.35 The IL-1 family in cancer inflammation. Alberto Mantovani. Humanitas University. Milan, Italy
• 9.35 - 9.45 Q&A
• 9.45 - 10.20 Exploitation of cancer neoantigens. Beatriz Carreño. University of Pennsylvania School of Medicine. USA
• 10.20 - 10.30 Q&A

10.30 - 11.00 Descanso café / Coffee break

11.00 - 12.45 ESIÓN 4 / SESSION 4
Chair: Christian Blank. Netherlands Cancer Institute. The Netherlands

• 11.00 - 11.30 Towards clinical development of radioimmunotherapy strategies. María Rodríguez Ruiz. CUN. Spain
• 11.30 - 12.00 Heterogeneity of immune biomarkers in NSCLC. Crispin Halley. UCL. London
• 12.00 - 12.30 Combining radiotherapy and immunotherapy. Tim Ilidge. Cancer Research UK Manchester Institute
• 12.30 - 12.45 Q&A

12.45 - 13.50 SESSION 5
Chair: Ignacio Melero. CIMA y CUN

• 12.45 - 13.15 Immunotherapy of hepatocellular carcinoma. Bruno Sangro. CUN. Spain
• 13.15 - 13.45 NASH and hepatocellular carcinoma-immunotherapy. Mathias Heikenwälder. German Cancer Research Center. Heidelberg, Germany
• 13.45 - 13.55 Q&A

13.55 - 16.00 COMIDA / LUNCH

16.00 - 17.45  SESIÓN 6 / SESSION 6 
Chair: Chair: Fernando Pastor. CIMA. Spain

• 16.00 - 16.30 TGFβ in colon cancer immunology. Eduard Batlle. IRB Barcelona. Spain
• 16.30 - 17.00 LIF in cancer immunology and immunotherapy. Joan Seoane. VHIO. Barcelona, Spain
• 17.00 - 17.30 Dissecting and modulating anti-cancer immunity in patient-derived tumor fragments. Daniela Thommen. Netherlands Cancer Institute. The Netherlands
• 17.30 - 17.45 Q&A

CLAUSURA / ADJOURN